InsiderTrades

Atlas Venture Opportunity Fund I, L.P.

SEC CIK 1759241 · EDGAR

Buying vs selling by month open-market trades, last 60 months, all 2 companies
BoughtSold

Companies

TickerCompanyTitleHoldingBoughtSoldTradesFirstLast
KYMRKymera Therapeutics, Inc.10% 5.05M — $3.82M 22023-01-112023-01-11
XLOXilio Therapeutics, Inc.10% 1.40M $3.00M — 22021-10-262021-10-26

Most active insiders at KYMR, 12 months

#InsiderTitleBoughtSold
1 Booth BruceDir —$226.03M
2 BVF PARTNERS L P/ILDir, See Remarks, Footnotes —$173.67M
3 BAKER FELIXDir, 10% $172.50M—
4 Mainolfi NelloCEO, Dir —$33.41M
5 Chadwick Jeremy GCOO —$15.60M
6 Jacobs Bruce N.CFO —$9.96M
7 Gollob JaredChief Medical Off —$9.13M
8 Esposito PamelaDir —$3.05M
9 Goodman NoahChief Business Off —$2.22M
10 Ridloff ElenaDir —$1.29M

Atlas Venture Opportunity Fund I, L.P. made no open-market trades at KYMR in the last 12 months.

Transactions 4

Type
Reset
X Filed Traded Ticker Company Insider Title Type Price Qty Owned ΔOwn Value
M 2023-01-13 2023-01-11+ KYMR Kymera Therapeutics, Inc. Atlas Venture Opportunity Fund I, L.P. 10% S - Sale $30.22 -98.8K 5.05M -2% -$2.99M
MI 2023-01-13 2023-01-11+ KYMR Kymera Therapeutics, Inc. Atlas Venture Opportunity Fund I, L.P. 10% S - Sale $30.22 -27.7K 890.1K -3% -$835.9K
DMI 2021-10-26 2021-10-26 XLO Xilio Therapeutics, Inc. Atlas Venture Opportunity Fund I, L.P. 10% C - Cnv Deriv — +2.55M 1.40M New —
DI 2021-10-26 2021-10-26 XLO Xilio Therapeutics, Inc. Atlas Venture Opportunity Fund I, L.P. 10% P - Purchase $16.00 +187.5K 735.9K +34% +$3.00M

Purchase Sale Sale after option exercise All abbreviations